Global investment firm KKR is in talks to acquire Leixir Dental Laboratory Group from Comvest Investment Partners at a valuation of $200-$250 million. Leixir, founded in 2013, offers various dental solutions and operates facilities in the US and India. Deloitte is advising on the sale process.

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, recently launched in India. Priced significantly lower than in the US, Mounjaro's introduction anticipates strong demand in the country with over 100 million obese and diabetic individuals.

Gnanamma Healthcare Centre in Guwahati celebrates its transition to a near net-zero electricity facility with a new 6.05kW solar plant and battery energy storage. This upgrade ensures reliable power, especially for critical services like vaccine storage and emergency care, reducing carbon emissions and setting an example for sustainable healthcare in the region.

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce weight-loss drugs in the market. The economic impact is enormous, and local generics are preparing to offer more affordable alternatives to combat this growing health issue.

Frequent use of steroid-based treatments for respiratory issues, allergies, and skin conditions can heighten the risk of glaucoma. Experts at AIIMS stress the importance of regular eye check-ups for early detection. Lifelong care and awareness programs at the primary care level are essential for preserving vision.

Dr. Reddys Laboratories is recalling a batch of Levetiracetam injection bags in the U.S. due to incorrect labeling, which could result in patients receiving a double dose. The error poses serious health risks, including hypersensitivity, liver injury, and respiratory depression. The mislabeled batch was distributed nationwide between November 4 and 6, 2024.

The Department of Pharmaceuticals has invited expressions of interest from various entities for project funding under the PRIP scheme, which aims to transform India into a global R&D powerhouse in the Pharma MedTech sector. Announced on August 17, 2023, the scheme has a financial outlay of Rs 5,000 crore, with Rs 4,250 crore dedicated to R&D investments.